User profiles for Michael Boeckh
 | Michael Boeckh, MDProfessor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center Verified email at fredhutch.org Cited by 56537 |
Quantitation of cytomegalovirus: methodologic aspects and clinical applications
Cytomegalovirus (CMV) is an important pathogen in transplant recipients and human
immunodeficiency virus (HIV)-infected individuals. Major progress has been made in developing …
immunodeficiency virus (HIV)-infected individuals. Major progress has been made in developing …
How we treat cytomegalovirus in hematopoietic cell transplant recipients
M Boeckh, P Ljungman - Blood, The Journal of the American …, 2009 - ashpublications.org
Cytomegalovirus (CMV) continues to cause major complications after hematopoietic cell
transplantation (HCT). Over the past decade, most centers have adopted preemptive antiviral …
transplantation (HCT). Over the past decade, most centers have adopted preemptive antiviral …
The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive …
M Boeckh, WG Nichols - Blood, 2004 - ashpublications.org
In the current era of effective prophylactic and preemptive therapy, cytomegalovirus (CMV)
is now a rare cause of early mortality after hematopoietic stem cell transplantation (HSCT). …
is now a rare cause of early mortality after hematopoietic stem cell transplantation (HSCT). …
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America
…, EJ Bow, KA Sepkowitz, MJ Boeckh… - Clinical infectious …, 2011 - academic.oup.com
This document updates and expands the initial Infectious Diseases Society of America (IDSA)
Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It …
Fever and Neutropenia Guideline that was published in 1997 and first updated in 2002. It …
Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized …
To determine whether cytomegalovirus (CMV) antigenemiaguided ganciclovir treatment may
be as effective, may require less treatment, and thus may cause less marrow toxicity than …
be as effective, may require less treatment, and thus may cause less marrow toxicity than …
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
M Boeckh, W Leisenring, SR Riddell… - Blood, The Journal …, 2003 - ashpublications.org
Ganciclovir effectively prevents cytomegalovirus (CMV) disease in the first 100 days after
allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is …
allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is …
[HTML][HTML] Cytomegalovirus: pathogen, paradigm, and puzzle
M Boeckh, AP Geballe - The Journal of clinical investigation, 2011 - Am Soc Clin Investig
Human cytomegalovirus (CMV), one of the eight herpesviruses that commonly infect
humans, is best known for its propensity to cause disease in immunocompromised patients, …
humans, is best known for its propensity to cause disease in immunocompromised patients, …
[HTML][HTML] Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation
Background Toll-like receptors (TLRs) are essential components of the immune response to
fungal pathogens. We examined the role of TLR polymorphisms in conferring a risk of …
fungal pathogens. We examined the role of TLR polymorphisms in conferring a risk of …
[HTML][HTML] Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective
M Tomblyn1, T Chiller2, H Einsele3, R Gress4, K Sepkowitz5, J Storek6, JR Wingard7, J-AH
Young8 and MJ Boeckh9
Young8 and MJ Boeckh9
[HTML][HTML] Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies
M Boeckh, WG Nichols, G Papanicolaou… - Biology of Blood and …, 2003 - Elsevier
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after hematopoietic
stem cell transplantation. Significant progress has been made in the prevention of CMV …
stem cell transplantation. Significant progress has been made in the prevention of CMV …
